Overactive Bladder News and Research

RSS

Overactive bladder (OAB) is a urological condition defined by a set of symptoms: "urgency, with or without urge incontinence, usually with frequency and nocturia."

Merck full-year 2012 worldwide sales decrease 2% to $47.3 billion

Merck, known as MSD outside the United States and Canada, today announced financial results for the fourth quarter and full year of 2012.

1 Feb 2013

Merck receives FDA approval for Oxytrol to treat overactive bladder in women

The U.S. Food and Drug Administration today approved Oxytrol for Women, the first over-the-counter treatment for overactive bladder in women ages 18 years and older.

28 Jan 2013

FDA approves Allergan’s BOTOX to treat overactive bladder

Allergan, Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved BOTOX (onabotulinumtoxinA) for the treatment of overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency and frequency in adults who have had an inadequate response to or are intolerant of an anticholinergic medication.

19 Jan 2013

Allergan receives FDA approval for Botox to treat overactive bladder

The U.S. Food and Drug Administration today expanded the approved use of Botox (onabotulinumtoxinA) to treat adults with overactive bladder who cannot use or do not adequately respond to a class of medications known as anticholinergics.

18 Jan 2013

Vaginal transobturator tape boosts incontinence cure rates

Implantation of tension-free vaginal transobturator tape is a highly effective and long lasting treatment for women with stress urinary incontinence.

31 Dec 2012

New coverage decisions by private payers and Medicare for OAB and urge incontinence

Uroplasty, Inc., a medical device company that develops, manufactures and markets innovative proprietary products to treat voiding dysfunctions, today announced significant new coverage decisions by private payers and Medicare.

27 Nov 2012

Adrenoreceptor shows potential in overactive bladder treatment

Mirabegron, a β3-adrenoreceptor agonist, has shown 12-month safety, tolerability, and persistence of effect in patients with overactive bladders, show study findings.

14 Nov 2012

National Association For Continence to host free educational events from Nov. 12 - 16

The National Association For Continence (NAFC) is hosting free educational events during National Bladder Health Week. Bladder Health Week occurs every year during the second full week in November. This year Bladder Health Week will be held from November 12 - 16.

7 Nov 2012

NAFC conducts online survey to examine women’s perceptions about overactive bladder

The National Association For Continence (NAFC) is conducting an anonymous online survey to understand the perceptions women, age 40-65, have about overactive bladder (OAB) and what they are prepared to do about its symptoms. Using constructs from the Health Belief Model, this survey aims to explain the fears and preparedness women have towards general health and OAB. This research is conducted by Kelton Global Research, a market research company and supported by a grant from Merck Pharmaceuticals.

26 Oct 2012

AUA introduces new guidelines for treatment of OAB, urodynamics, hematuria and vasectomy

The American Urological Association (AUA) introduces new clinical guidelines for the treatment of Overactive Bladder, Urodynamics, Hematuria, and Vasectomy.

24 Oct 2012

Oral medication as effective as Botox injections for treating incontinence in women

Oral medication for treating a type of incontinence in women is roughly as effective as Botox injections to the bladder, reported researchers who conducted a National Institutes of Health clinical trials network study, with each form of treatment having benefits and limitations.

6 Oct 2012

Positive results from Antares Pharma’s VIBEX MTX clinical study on rheumatoid arthritis

Antares Pharma, Inc. today announced positive results from an Actual Human Use (AHU) study for VIBEX Methotrexate (MTX).

25 Sep 2012

Antimuscarinics only moderately effective for overactive bladder

A comprehensive review of oral antimuscarinics for the treatment of overactive bladder concludes that the efficacy of treatment is, at best, moderate.

17 Sep 2012

Pfizer, Mylan enter settlement agreement to resolve generic Detrol LA litigation

Mylan Inc. today announced that it and its subsidiary, Mylan Pharmaceuticals Inc., have entered into a settlement agreement with Pfizer Inc., Pharmacia & Upjohn Company LLC and Pfizer Health AB that will resolve the parties' patent litigation in connection with Mylan Pharmaceuticals' Abbreviated New Drug Application (ANDA) for Tolterodine Tartrate ER capsules, 2 mg and 4 mg, which is the generic version of Pfizer's Detrol LA, indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and frequency.

7 Sep 2012

Targacept plans to pursue development of TC-5214 for overactive bladder

Targacept, Inc., a clinical-stage biopharmaceutical company developing novel NNR Therapeutics, today announced that it plans to pursue development of TC-5214 as a treatment for overactive bladder (OAB).

6 Sep 2012

Link between sleep apnoea and overactive bladder syndrome in women

Sleep apnoea in women has been linked to overactive bladder syndrome in a new study. The research, presented at the European Respiratory Society's Annual Congress in Vienna, has provided new evidence suggesting a connection between the two conditions.

3 Sep 2012

Uroplasty first quarter global sales increase 20% to $5.6 million

Uroplasty, Inc., a medical device company that develops, manufactures and markets innovative proprietary products to treat voiding dysfunctions, today reported financial results for the first quarter of fiscal 2013 ended June 30, 2012.

26 Jul 2012

Nerve growth factors sense OAB in children

Researchers may have found a reliable biomarker for diagnosing overactive bladder in children and monitoring their treatment outcome.

18 Jul 2012

Astellas Pharma receives FDA approval for Myrbetriq to treat overactive bladder

The U.S. Food and Drug Administration today approved Myrbetriq (mirabegron) to treat adults with overactive bladder, a condition in which the bladder muscle cannot be controlled, squeezes too often or squeezes without warning.

29 Jun 2012

Positive results from Antares Pharma's VIBEX MTX human factors usability study for RA

Antares Pharma, Inc. today announced positive results from a human factors usability study for VIBEX Methotrexate (MTX), a proprietary auto injector product designed to self-administer a rapid subcutaneous weekly injection of methotrexate for the treatment of rheumatoid arthritis (RA).

26 Jun 2012